Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Medtronic
Cantor Fitzgerald
McKesson
Queensland Health
Colorcon
Moodys
Mallinckrodt
UBS

Generated: May 23, 2018

DrugPatentWatch Database Preview

CABERGOLINE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for CABERGOLINE
Pharmacology for CABERGOLINE
Ingredient-typeErgolines
Drug ClassErgot Derivative
Synonyms for CABERGOLINE
(6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea
1-[3-(DIMETHYLAMINO)PROPYL]-3-ETHYL-1-[(2R,4R,7R)-6-(PROP-2-EN-1-YL)-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(15),9,12(16),13-TETRAENE-4-CARBONYL]UREA
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0;{2,7}.0;{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
409C907
6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide
81409-90-7
85329-89-1 (diphosphate)
AB01275484-01
AC-26126
AC1L1HO0
AC1Q5OQ0
AKOS015961587
AN-36255
BC207368
BDBM50426497
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergoline, >=98% (HPLC)
Cabergoline, European Pharmacopoeia (EP) Reference Standard
Cabergoline, United States Pharmacopeia (USP) Reference Standard
Cabergolinum
Cabergolinum [Latin]
Caberlin
CAS-81409-90-7
CG-101
CHEBI:3286
CHEMBL1201087
CTK8F8406
D00987
D04EGX
DB00248
Dostinex
Dostinex (TN)
DR002797
DSSTox_CID_2719
DSSTox_GSID_22719
DSSTox_RID_76698
DTXSID6022719
Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-
Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-
FCE-21336
FT-0081285
FT-0650562
Galastop
GTPL37
HMS2090A09
K450
KORNTPPJEAJQIU-KJXAQDMKSA-N
LL60K9J05T
LS-64370
MFCD00867887
MolPort-003-845-557
N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide
NCGC00167821-01
NCGC00344544-01
PL070592
SC-19831
SCHEMBL42292
Sogilen
SR-05000001493
SR-05000001493-2
Tox21_112589
Tox21_112589_1
UNII-LL60K9J05T
ZINC3800008

US Patents and Regulatory Information for CABERGOLINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl Inc CABERGOLINE cabergoline TABLET;ORAL 078035-001 Apr 21, 2008 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ivax Sub Teva Pharms CABERGOLINE cabergoline TABLET;ORAL 077750-001 Mar 7, 2007 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Apotex Corp CABERGOLINE cabergoline TABLET;ORAL 201503-001 Mar 8, 2013 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Impax Labs Inc CABERGOLINE cabergoline TABLET;ORAL 077843-001 Jul 3, 2007 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Baxter
QuintilesIMS
Fuji
Argus Health
Farmers Insurance
Harvard Business School
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.